FDA
-
-
-
-
-
-
-
The U.S. Food and Drug Administration Completes Review of Cibus’ Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
-
-
-
-
-
-
-
Cellectis (CLLS) Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
-
-
-
-
-
-
-
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
-
-
-
-
-
-
-
After-Hours Stock Movers 07/06: (GLDD) (XPSA) Higher; (MARK) (CLLS) (PING) Lower (more...)
-
-
-
-
-
-
-
First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
-
-
-
-
-
-
-
Calyxt Reports 1st Quarter Financial Results
-
-
-
-
-
-
-
Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

